Coadministration of Cardiomagnyl with Edarbi/Edarbi Clo in comparison with enteric-coated acetylsalicylic acid and renin-angiotensin-aldosterone system blockers in patients with hypertension and atherosclerotic cardiovascular diseases in the Russian Federation. Results of the CARAT study

Coadministration of Cardiomagnyl with Edarbi/Edarbi Clo in comparison with enteric-coated acetylsalicylic acid and renin-angiotensin-aldosterone system blockers in patients with hypertension and atherosclerotic cardiovascular diseases in the Russian Federation. Results of the CARAT study

Aim. To compare clinical outcomes in patients with hypertension and atherosclerotic cardiovascular diseases (CVDs) prescribed a combination of buffered acetylsalicylic acid (BA) (Cardiomagnyl®) + Azilsartan/Azilsartan+chlorthalidone (Edarbi/Edarbi Clo®) or enteric-coated acetylsalicylic acid (ECA) +...

Full description

Saved in:
Bibliographic Details
Main Authors: F. T. Ageev, M. D. Smirnova, A. N. Kaftanov, D. V. Gavrilov
Format: Article
Language:Russian
Published: «FIRMA «SILICEA» LLC 2025-07-01
Series:Российский кардиологический журнал
Subjects:
atherosclerotic cardiovascular diseases
hypertension
major adverse cardiovascular events
acetylsalicylic acid
azilsartan
chlorthalidone
real-world practice
Online Access:https://russjcardiol.elpub.ru/jour/article/view/6373
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://russjcardiol.elpub.ru/jour/article/view/6373

Similar Items